Research Ethics and the Human Subjects Framework

Lesson 7.1 · 13 min

Adverse event documentation concepts

An adverse event, in research terms, is any unfavorable and unintended sign, symptom, or outcome that occurs during a research activity, whether or not it is believed to be related to the substance or procedure under study. The habit of documenting these events, promptly, completely, and without editorializing about cause, is a core research skill distinct from providing medical care.

A usable adverse event record states what was observed, when, in what temporal relationship to the research activity, its apparent severity, and what happened afterward, without inserting an unsupported causal conclusion into the record itself. Causality assessment is a separate, more difficult step that should not be conflated with the observation.

In formal research settings, adverse event reporting has legally defined timelines and destinations, for example to a sponsor, an IRB, or a regulator, depending on severity and context. Informal researchers do not have those reporting obligations, but the underlying discipline, capturing unexpected harm accurately and promptly rather than minimizing or ignoring it, is equally important and this course teaches it as a research competency, not as a substitute for seeking medical care when needed.

Adverse event:

Any unfavorable, unintended sign, symptom, or outcome occurring during a research activity, recorded regardless of presumed cause.

Causality assessment:

A distinct, separate judgment about whether an adverse event was plausibly caused by the research activity, which should not be blended into the initial factual record.

Lesson 7.2 · 15 min

IRB review, informed consent, and the Common Rule

In the United States, research involving human subjects that is conducted or funded by federal agencies, or by institutions that have agreed to apply the standard more broadly, is generally governed by a shared set of protections known as the Common Rule, codified at 45 CFR 46. Its core mechanism is independent review of a research plan by an Institutional Review Board, or IRB, before the research begins, along with a documented informed consent process for participants.

An IRB's role, in general terms, is to evaluate whether risks to participants are minimized and reasonable in relation to anticipated benefits, whether selection of subjects is equitable, and whether informed consent will be properly obtained and documented. Informed consent, as a concept, means a prospective participant is given the information a reasonable person would need to decide whether to take part, and gives that consent voluntarily, without coercion, before participation begins.

Whether a particular activity legally counts as human subjects research subject to these requirements, and whether a particular institution or individual is bound by them, is a fact-specific determination that depends on funding source, institutional agreements, and the precise nature of the activity. This course explains the concepts so you can recognize when a project resembles regulated human subjects research; it does not and cannot tell you whether your specific activity is covered. That determination is not legal advice and should be made with reference to the regulation itself and, where uncertainty exists, appropriate professional or regulatory guidance.

Institutional Review Board (IRB):

A committee charged with reviewing and monitoring research involving human subjects to protect their rights and welfare.

Informed consent:

A documented process by which a prospective participant is given adequate information and voluntarily agrees to take part in research.

Lesson 7.3 · 15 min

The IND framework, sponsors, and investigators

Under federal law, a drug generally must be the subject of an approved marketing application, or be studied under an Investigational New Drug application, or IND, before it is shipped or used for the purpose of conducting a clinical investigation in people. This framework is set out at 21 CFR Part 312. In broad terms, an IND is a submission to the FDA that allows a sponsor to legally ship an unapproved drug across state lines for the purpose of conducting a clinical trial, subject to specific safety and reporting obligations.

The regulation distinguishes roles: a sponsor is the party that initiates and takes responsibility for a clinical investigation, an investigator is the individual who actually conducts it, and a sponsor-investigator is a single person who does both, taking on the combined regulatory obligations of each role. These obligations include maintaining the investigational plan, ensuring IRB approval and ongoing review, obtaining informed consent, monitoring for and reporting adverse events on defined timelines, and maintaining records the FDA can inspect.

Administering an unapproved research chemical to a person, including oneself, outside of an IND and outside IRB oversight, sits well outside this framework and carries legal and safety exposure that this course does not evaluate for any individual situation. Whether a specific activity requires an IND, falls under an exemption, or is regulated at all is a fact-specific legal question. This course explains the concepts that exist in the regulation; it is education, not legal advice, and a person facing this question in practice should look to the regulation itself and appropriate professional or regulatory guidance rather than to this material.

Investigational New Drug (IND):

An FDA application and framework that permits legal shipment and clinical study of an unapproved drug, subject to safety oversight.

Sponsor-investigator:

A single individual who both initiates a clinical investigation and personally conducts it, holding the combined regulatory responsibilities of a sponsor and an investigator.

Lesson 7.4 · 14 min

State versus federal regulation, and when to seek additional guidance

Federal regulations such as the Common Rule and the IND framework set a floor and a structure, but they do not sit alone. State law can separately regulate the practice of medicine, human experimentation, controlled substances, professional licensing, and consumer protection, and state requirements can be more restrictive than federal ones or can apply in situations federal rules do not directly reach. An activity that appears to fall outside federal human subjects rules can still be squarely regulated at the state level.

Two related federal protections for research subjects specifically involving human beings are informed consent requirements at 21 CFR Part 50 and IRB requirements at 21 CFR Part 56, which apply to clinical investigations regulated by FDA. These sit alongside, and overlap in places with, the Common Rule at 45 CFR 46. The overlapping and sometimes non-identical scope of these frameworks is itself a reason that coverage questions are fact-specific rather than answerable in general terms.

As a practical matter, an activity likely warrants additional authorization or professional regulatory guidance, beyond anything this course can supply, when it involves administering a substance to another person, when it involves any exchange of money or service for participation, when results will be used to support a marketing or health claim, when a person other than the researcher bears the risk, or when the researcher is uncertain whether the activity has crossed from personal handling into research involving another human subject. None of these triggers are exhaustive, and their presence does not itself resolve the legal question.

This entire lesson is educational background on a public regulatory framework, not legal advice, and not a determination about any individual's situation. Where real uncertainty exists, the appropriate step is to consult the primary regulatory text directly and, where warranted, a qualified attorney or the relevant regulatory body, not to rely on a certification course to make the determination.

Common Rule:

The baseline federal human subjects protection framework at 45 CFR 46, applicable to research conducted or funded by covered federal agencies or bound institutions.